ATAI
Closed
Atai Life Sciences Bv
2.71
+0.52 (+23.74%)
Last Update: 01 Jul 2025 23:19:00
Yesterday: 2.19
Day's Range: 2.36 - 2.895
Send
sign up or login to leave a comment!
When Written:
1.81
ATAI Life Sciences BV is a biotech company that focuses on developing innovative treatments for mental health disorders. The company was founded in 2018 by Christian Angermayer, Florian Brand, and Lars Wilde. ATAI Life Sciences BV is headquartered in Berlin, Germany, and has additional offices in New York City and London.
The company is focused on developing psychedelic drugs, which are believed to have potential therapeutic benefits for mental health disorders such as depression, anxiety, and addiction. ATAI Life Sciences BV is currently working on several clinical trials for its pipeline of psychedelic drugs, including compounds like psilocybin, ketamine, and ibogaine.
ATAI Life Sciences BV has also invested in several other biotech companies that are working on developing treatments for mental health disorders. The company has raised over $300 million in funding to date, and its investors include Peter Thiel, Mike Novogratz, and Steve Jurvetson.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company is focused on developing psychedelic drugs, which are believed to have potential therapeutic benefits for mental health disorders such as depression, anxiety, and addiction. ATAI Life Sciences BV is currently working on several clinical trials for its pipeline of psychedelic drugs, including compounds like psilocybin, ketamine, and ibogaine.
ATAI Life Sciences BV has also invested in several other biotech companies that are working on developing treatments for mental health disorders. The company has raised over $300 million in funding to date, and its investors include Peter Thiel, Mike Novogratz, and Steve Jurvetson.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








